Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.
Influenza Virus Vaccine Adverse Reaction (Disorder)|Influenza|Malignancy
BIOLOGICAL: influenza vaccination
Number of participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab., participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab., October 1st 2016 to March 31st 2017
Number of participants with adverse events and grading of adverse event as measured by the adverse events toxicity scale., participants with adverse events, October 1st 2016 to March 31st 2017|Number of participants requiring hospitalizations for adverse events or influenza infection., participants requiring hospitalizations, October 1st 2016 to March 31st 2017|Number of participants with seroconversion as assessed by influenza A and B IgM and IgG titers., participants with seroconversion, October 1st 2016 to March 31st 2017
The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.